阿立哌唑和利培酮治疗老年性精神分裂症的对照研究q(1)
 |
| 第1页 |
参见附件(1263KB，2页)。
【摘要】 目的 探讨阿立哌唑对老年性精神分裂症患者的疗效、不良反应及生存质量的影响。方法 将80例老年性精神分裂症患者随机分为阿立哌唑组与利培酮组,治疗观察12周。以阳性和阴性症状量表(PANSS)、世界卫生组织生活质量量表(WHQOL-100)、治疗中出现的症状量表(TESS)评定疗效、生存质量及不良反应。结果 阿立哌唑组与利培酮组疗效相当,两组患者的PANSS评分均明显减少,差异有显著性(P<0.01);两组间无显著差异(P>0.05)。两组WHQOL-100评分均较治疗前有显著改善(P<0.01),两组间无显著差异(P>0.05)。阿立哌唑组锥体外系反应、心动过速及体重增加等不良反应发生率显著低于利培酮组,差异有显著性(P<0.01)。结论 阿立哌唑对老年性精神分裂症有良好的疗效,能有效改善患者的生存质量,且安全性高,依从性好,适合老年性精神分裂症患者使用。
【关键词】 老年性精神分裂症;阿立哌唑;利培酮;生存质量
Comparative study on elderly schizophrenics by aripiprazole and risperidone
CHEN Yong-hong. Mental Hospital of The Fifth Company of China Coal Group, Xuzhou 221600,China
【Abstract】 Objective To compare the efficacy,quality of life and safety of aripiprazole to treat elderly schizophrenics.Methods 80 elderly schizophrenic patients were randomly divided into aripiprazole group and risperidonegroup for 12 weeks.The efficacy was measured with Positive and Negative Syndrome Scale for schizophrenia (PANSS),the side effects were assessed by the treatment emergent symptom scale (TESS),the WHO Quality of Life-100 scale(WHQOL-100)for quality of life.Results By the end of the 12 weeks,the scores of PANSS and WHQOL-100 in two groups changed notably (P<0.01)。There was no significant difference between the two groups (P>0.05)。The occurrence rate of extrayramidal side effects,tachycardia and increased weight in the aripiprazole group was significantly lower than in the rispridone group (P<0.01).Conclusion The results suggest that aripiprazole is effective,safety and good compliance for the treatment of elderly schizophrenics,It can improve the patients,quality of life efficiently,Aripiprazole is beneficial for elderly schizophrenia.
【Key words】 Elderly schizophrenia; Aripiprazole; Risperidone;Quality of life
作者单位:221600 江苏省沛县中煤五公司精神病院
老年性精神分裂症患者由于生理变化和代谢缓慢等特点,其对药物敏感性高,耐受性低,因此治疗老年性精神分裂症,应选择合适的用药。阿立哌唑作为新型非经典抗精神病药物,有研究显示,其对精神分裂症阳性症状和阴性症状均有效,并可改善患者的认知功能,且不良反应小[1,2,3]。本研究选用阿立哌唑(商品名:奥派)与利培酮(商品名:维思通)治疗老年性精神分裂症,评定阿立哌唑对老年性精神分裂症的疗效及不良反应,以及对患者生存质量的影响。
1 资料与方法
1.1 一般资料 为我院2008年1月至2009年12月期间住院患者,符合CCMD-3精神分裂症诊断标准,PANSS总分≥60,年龄60~75岁。排除严重的躯体疾病、酒精及物质依赖和药物过敏。入组前一周未服用抗精神病药物或一月内未注射长效抗精神病药,家属知情同意,共80例,按住院顺序随机平均分为两组:阿立哌唑组40例,男30例,女10例;年龄(63 ......
您现在查看是摘要介绍页，详见PDF附件(1263KB，2页)。